|
|
Volumn 2008, Issue 3, 2008, Pages 45-54
|
|
Therapies to increase ApoA-I and HDL-cholesterol levels
a
|
|
Author keywords
Apolipoprotein A I (ApoA I); Atherosclerosis; Cholesterol; Dyslipidemia; High density lipoprotein (HDL); Reverse cholesterol transport (RCT); Transcription
|
|
Indexed keywords
2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER;
2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2 4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID;
AG 1067;
ANTILIPEMIC AGENT;
APOLIPOPROTEIN A1;
ATORVASTATIN;
CHOLESTEROL ESTER TRANSFER PROTEIN;
CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR;
CONJUGATED ESTROGEN;
CSL 111;
ESTROGEN;
ETC 216;
FIBRIC ACID DERIVATIVE;
GEMFIBROZIL;
HIGH DENSITY LIPOPROTEIN;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LIPOSOME;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
MEVINOLIN;
NICOTINIC ACID;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;
PHOSPHATIDYLINOSITOL;
PLACEBO;
POLYPHENOL DERIVATIVE;
PROBUCOL SUCCINATE;
RECOMBINANT PROAPOLIPOPROTEIN A1;
RESVERATROL;
RIMONABANT;
TORCETRAPIB;
UNINDEXED DRUG;
ARTERY WALL;
ATHEROGENESIS;
ATHEROSCLEROSIS;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CHOLESTEROL BLOOD LEVEL;
CHOLESTEROL TRANSPORT;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
DIET THERAPY;
DISEASE ASSOCIATION;
DISEASE COURSE;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG TARGETING;
DYSLIPIDEMIA;
ESTROGEN THERAPY;
FAMILIAL HYPOALPHALIPOPROTEINEMIA;
FLUSHING;
HORMONE SUBSTITUTION;
HUMAN;
INCIDENCE;
LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;
LIFESTYLE MODIFICATION;
LIPID METABOLISM;
LOW DRUG DOSE;
MONOTHERAPY;
NONHUMAN;
PROTEIN DEFICIENCY;
PROTEIN FUNCTION;
PROTEIN LIPID INTERACTION;
PROTEIN SYNTHESIS;
REMISSION;
REVIEW;
SIDE EFFECT;
SINGLE DRUG DOSE;
SUSTAINED RELEASE FORMULATION;
TANGIER DISEASE;
UNSPECIFIED SIDE EFFECT;
|
|
EID: 55549097891
PISSN: None
EISSN: 11773928
Source Type: Journal
DOI: 10.4137/dti.s447 Document Type: Review |
|
Times cited : (5)
|
|
References (85)
|
